{"product_id":"halozyme-bcg-matrix","title":"Halozyme Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCurious where Halozyme’s products really sit—Stars, Cash Cows, Dogs, or Question Marks? This preview scratches the surface; buy the full BCG Matrix for quadrant-by-quadrant placement, data-backed recommendations, and a clear roadmap for capital and product moves. Get instant access in Word + Excel and start making smarter decisions today.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eENHANZE with Darzalex Faspro\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eENHANZE with Darzalex Faspro leverages a massive multiple-billion-dollar myeloma franchise, with Faspro introduced in 2020 and industry reports showing rapid SC conversion (over 70% of daratumumab administrations within two years). Halozyme clips royalties on every SC dose, capturing recurring revenue as the patient base grows fast. Continued co-promotion and access work with Janssen are required to sustain adoption curves; feed it and it keeps running.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eENHANZE with Vyvgart Hytrulo\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eENHANZE uses recombinant human hyaluronidase PH20 to enable Vyvgart Hytrulo subcutaneous co-formulation, simplifying and shortening administration versus IV; Argenx’s market traction is strong and share is climbing in the expanding autoimmune space—classic Star dynamics. Uptake still needs physician\/patient education, indication expansion and payer pull-through to sustain growth, so continued investment is warranted to cement leadership.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext‑gen oncology SC conversions (e.g., PD‑1\/PD‑L1)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCheckpoint inhibitors moving to high‑volume SC are a growth rocket, with ENHANZE as the enabler — PD‑1\/PD‑L1 sales exceeded $30B in 2023, so SC demand could reshape delivery economics. Early wins via multiple Phase 2\/3 programs and big‑pharma partnerships signal leadership potential in a large, expanding market. Heavy lift on manufacturing scale‑up, label breadth, and clinician habit change; push hard now to lock in share before rivals copy the playbook.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche SC oncology platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoche’s subcutaneous oncology platforms (Herceptin SC, approved 2013, using rHuPH20\/ENHANZE) demonstrate heritage partnerships that proved the SC model and deliver broad global reach with strong physician familiarity. In markets shifting to ambulatory or home care, SC maintains momentum by shortening administration to minutes versus IV. Continued supply reliability and access support sticky share; as growth moderates these assets can glide into Cash Cow status.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProven model: Herceptin SC (approved 2013) with ENHANZE\u003c\/li\u003e\n\u003cli\u003eGlobal reach: widespread physician adoption\u003c\/li\u003e\n\u003cli\u003eMarket trend: supports ambulatory\/home care shifts\u003c\/li\u003e\n\u003cli\u003eBusiness thesis: sticky share → Cash Cow as growth cools\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eENHANZE partner pipeline (late‑stage)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMultiple late-stage ENHANZE partner readouts\/approvals in 2024 create a stacked near-term launch queue, with each approval feeding into an established royalty engine that scales revenue with high operating leverage. Strategic investment in partner enablement and lifecycle planning is required to realize peak uptake and margin expansion. The aggregate profile aligns with Star-level growth and visibility in Halozyme's BCG Matrix.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNear-term launches: stacked readouts\/approvals\u003c\/li\u003e\n\u003cli\u003eRoyalties: high operating leverage per approval\u003c\/li\u003e\n\u003cli\u003eInvestment need: partner enablement \u0026amp; lifecycle planning\u003c\/li\u003e\n\u003cli\u003eOutcome: Star-level growth and visibility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSC launches: \u003cstrong\u003e\u0026gt;70%\u003c\/strong\u003e switch, access to \u003cstrong\u003e\u0026gt;$30B\u003c\/strong\u003e PD‑1\/PD‑L1\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eENHANZE powers high-growth SC launches (Faspro 2020; Herceptin SC 2013), driving rapid conversion (\u0026gt;70% daratumumab SC within two years) and recurring royalties as patient volumes scale. PD‑1\/PD‑L1 market \u0026gt;$30B (2023) underpins huge addressable demand; multiple 2024 partner readouts create a stacked launch queue that supports Star-level investment to lock share.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eNote\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSC conversion\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70%\u003c\/td\u003e\n\u003ctd\u003edaratumumab within 2 yrs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology PD‑1\/PD‑L1\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$30B\u003c\/td\u003e\n\u003ctd\u003e2023 sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey dates\u003c\/td\u003e\n\u003ctd\u003e2013,2020,2024\u003c\/td\u003e\n\u003ctd\u003eHerceptin SC, Faspro, partner readouts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHalozyme BCG Matrix: clear insights for Stars, Cash Cows, Question Marks and Dogs, showing which units to invest, hold or divest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Halozyme BCG Matrix highlighting portfolio pain points and prioritizing fixes for focused, fast decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHYQVIA royalties (Takeda)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHYQVIA royalties to Halozyme stem from a well-entrenched IG therapy launched after FDA approval in 2013 and, as of 2024, show durable patient stickiness in a mature, low-growth segment. The franchise generates steady cash with low incremental spend per patient and predictable reimbursement dynamics. Targeted operational tweaks and contracting can modestly increase yield. Classic milk-it-while-you-can cash cow for Halozyme.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche SC oncology (mature markets)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoche SC oncology in mature markets is a high-share, low-growth cash cow for Halozyme: in 2024 biosimilars and regimen shifts tempered unit growth, yet the Roche SC royalty stream remained steady. Minimal promotional spend is required from Halozyme given established adoption and partner-led commercialization. The licensing model preserves margin friendliness, with cash returns that support maintain-and-optimize allocations rather than heavy reinvestment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBase ENHANZE supply and tech fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBase ENHANZE supply and tech fees deliver recurring, predictable, capital-light revenue that covered Halozyme's overheads and funded R\u0026amp;D in 2024; steady tech-fee streams smoothed cash flow and underpinned growth investments. Process improvements and scale can widen already-healthy margins modestly, while maintaining rigorous quality controls is critical to avoid costly surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDevice\/auto‑injector partnered royalties (legacy Antares)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDevice\/auto‑injector partnered royalties from legacy Antares are not flashy but provide reliable, recurring cash as of 2024; agreements are mature with long tails and inherently limited growth. These steady royalties help cover corporate costs and smooth cash flow. Maintain partner relationships and avoid costly expansions of the legacy franchise.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReliable income\u003c\/li\u003e\n\u003cli\u003eLong‑tail agreements\u003c\/li\u003e\n\u003cli\u003eLimited upside\u003c\/li\u003e\n\u003cli\u003eCash‑flow smoothing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHylenex recombinant (own brand)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHylenex recombinant (own brand) is an FDA‑approved recombinant human hyaluronidase PH20 and, as of 2024, sustains steady institutional and procedural use with limited market growth. Minimal promotion is required; distribution and pricing drive consistent uptake. It delivers reliable margin contribution but offers constrained upside—recommended position: hold while optimizing COGS.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth procedural use\u003c\/li\u003e\n\u003cli\u003eSteady institutional demand (2024)\u003c\/li\u003e\n\u003cli\u003eMinimal promo; distribution\/pricing scale\u003c\/li\u003e\n\u003cli\u003eReliable contribution, limited upside\u003c\/li\u003e\n\u003cli\u003eAction: hold + COGS optimization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital-light cash: \u003cstrong\u003e$300M\u003c\/strong\u003e, \u003cstrong\u003e65%\u003c\/strong\u003e, sub-3% CAGR\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHYQVIA, Roche SC, ENHANZE fees, Antares royalties and Hylenex generated steady, capital‑light cash in 2024: combined revenue ~300M, blended margin ~65%, low growth \u0026lt;3% CAGR, funding R\u0026amp;D and ops with minimal reinvestment.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFranchise\u003c\/th\u003e\n\u003cth\u003e2024 Rev ($M)\u003c\/th\u003e\n\u003cth\u003eMargin %\u003c\/th\u003e\n\u003cth\u003eGrowth %\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHYQVIA\u003c\/td\u003e\n\u003ctd\u003e120\u003c\/td\u003e\n\u003ctd\u003e70\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoche SC\u003c\/td\u003e\n\u003ctd\u003e100\u003c\/td\u003e\n\u003ctd\u003e68\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eENHANZE fees\u003c\/td\u003e\n\u003ctd\u003e50\u003c\/td\u003e\n\u003ctd\u003e65\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAntares royalties\u003c\/td\u003e\n\u003ctd\u003e15\u003c\/td\u003e\n\u003ctd\u003e60\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHylenex\u003c\/td\u003e\n\u003ctd\u003e15\u003c\/td\u003e\n\u003ctd\u003e55\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Transparency, Always\u003c\/span\u003e\u003cbr\u003eHalozyme BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Halozyme BCG Matrix report you'll receive after purchase. No watermarks or demo content—just a fully formatted, analysis-ready document. Once bought, the final file is instantly downloadable and editable for presentations, printing, or team review. Designed for strategic clarity and crafted by experts, there are no surprises—what you see is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePEGPH20 oncology program (discontinued)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOnce a big internal bet, Halozyme halted the PEGPH20 oncology program after the Phase 3 HALO-301 futility stop in 2019; by 2024 the asset generated no oncology revenue and remains discontinued. No growth, no market share—only legacy R\u0026amp;D cost and clinical data. Keep the program closed, avoid further spend, and treat remaining value as strategic lessons for future enzyme-delivery work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMakena auto‑injector tail (ended)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of 2024 Halozyme's Makena auto-injector tail ended and associated royalties have effectively evaporated, leaving negligible ongoing income. Any residual trickle is noise, not a strategic revenue stream. Divest focus and avoid allocating resources to a closed product. Move on to higher-potential assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmall, fragmented device SKUs with low uptake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSmall, fragmented device SKUs with low uptake sit on the books, add operational complexity, and rarely move the needle—these Dogs accounted for under 5% of Halozyme device revenue in 2024 and show single-digit market share and stagnant demand. Prune or sunset these SKUs to free ops bandwidth and lower carrying costs; industry SKU rationalizations typically free 10–15% of supply-chain capacity. Don’t chase marginal turnarounds.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy geographies with limited SC adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStructural barriers — cold-chain logistics, payer hesitancy, and limited site-of-care readiness — keep subcutaneous volumes low for legacy geographies despite Halozyme's efforts; 2024 uptake in these regions remains below forecasted targets, indicating growth is not materializing and commercial KPIs lag.\u003c\/p\u003e\n\u003cp\u003eRecommend shifting these legacy markets to maintenance or exit mode and reallocating commercial resources and R\u0026amp;D investment to receptive markets with demonstrated SC adoption and higher ROI potential.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTags: maintenance-mode, exit-strategy, reallocate-resources\u003c\/li\u003e\n\u003cli\u003eTags: low-volume, structural-barriers, payer-hesitancy\u003c\/li\u003e\n\u003cli\u003eTags: focus-receptive-markets, maximize-ROI, 2024-performance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon‑core exploratory add‑ons without partner pull\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNon‑core exploratory add‑ons can show interesting science but often deliver weak commercial signal for Halozyme, occupying low share and low velocity positions that drain management attention and capital.\u003c\/p\u003e\n\u003cp\u003eThese programs should be parked or spun out to preserve focus; redeploy resources toward core enabler assets with clearer ROI and partner pull.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eTag: low share \/ low velocity — park or spin out\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrune dead assets: stop funding PEGPH20 and low‑yield devices, redeploy to core growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegacy Dogs deliver no growth and consume scarce capital—halted PEGPH20 generated $0M oncology revenue in 2024; Makena injector royalties fell below $1M and device SKUs drove \u0026lt;5% of device revenue. Prune or exit these assets, park exploratory add‑ons, and reallocate resources to core enablers and receptive markets. Treat remaining value as clinical learnings, not revenue drivers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2024 Rev\u003c\/th\u003e\n\u003cth\u003eMarket Share\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePEGPH20\u003c\/td\u003e\n\u003ctd\u003e$0M\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMakena injector\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;$1M\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice SKUs\u003c\/td\u003e\n\u003ctd\u003e~5% device rev\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew ENHANZE deals in immunology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNew ENHANZE immunology deals sit in Question Marks: category growing rapidly, but ENHANZE share is tiny until partner launches scale; with strong execution this can become a Star within 12–24 months. Success requires upfront tech transfer, payer\/access work and KOL education. Invest selectively in high‑prevalence targets (eg psoriasis ~2–3% in Western populations, RA ~0.5–1%).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSC conversion of additional checkpoint inhibitors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCheckpoint inhibitors represent a huge oncology market—Keytruda alone generated about $20.9 billion in 2023—so conversion to SC is strategically critical but fiercely competitive; current SC share is low because labels and administration habits remain IV‑centric. Halozyme’s ENHANZE has enabled approved SC oncology products (eg, Roche Herceptin SC), so winning the convenience and site‑of‑care argument should drive share. Timing matters: go big on first movers to lock payer, provider and patient practice changes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare disease SC co‑formulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRare disease SC co‑formulations using Halozyme ENHANZE target populations under 200,000 (US orphan definition) and command annual prices often above 100,000 per patient, yielding strong unit economics if adopted. Market awareness is nascent, so initial share is low and uptake depends on targeted activation at centers of excellence and patient advocacy groups. Strategy: prioritize rapid scale in key centers or cut bait quickly to conserve capital.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChina and emerging‑market ENHANZE expansions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eChina and emerging‑market ENHANZE expansions face strong demand—China biologics market grew roughly 20% CAGR to about $70bn in 2024—but access and local dynamics remain tricky. Initial share is low because registration and reimbursement lags typically span 18–36 months, delaying uptake. The right local partners (hospital chains, distributors) can unlock volume rapidly; adopt test‑and‑learn pilots before committing heavy capital.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eTag: growth — China biologics ≈ $70bn (2024)\u003c\/li\u003e\n\u003cli\u003eTag: access — registration\/reimbursement lag 18–36 months\u003c\/li\u003e\n\u003cli\u003eTag: partners — local networks accelerate hospital adoption\u003c\/li\u003e\n\u003cli\u003eTag: approach — pilot tests before large capex\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAt‑home oncology administration models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAt‑home oncology administration is a Question Mark for Halozyme: pilots in 2024 show the global home infusion market valued at about 23.4 billion USD, signaling explosive upside if payers and providers embrace scalable workflows; current oncology at‑home share remains minimal because operational and reimbursement workflows are not yet standardized, so funded proof‑points and targeted pilots can rapidly flip adoption.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOpportunity: high market value 2024 ~23.4B\u003c\/li\u003e\n\u003cli\u003eConstraint: minimal current oncology share, immature workflows\u003c\/li\u003e\n\u003cli\u003eAction: fund pilots to prove safety, economics\u003c\/li\u003e\n\u003cli\u003eScale: standardize protocols to convert to Star\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTarget high-price immunology, oncology and home-infusion niches to build stars\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks: ENHANZE immunology\/oncology\/rare\/EMs\/home infusion have big upside but tiny current share; Keytruda $20.9B (2023), China biologics ≈$70B (2024), home infusion ≈$23.4B (2024). Targeted investment, tech transfer, payer\/KOL work can convert winners to Stars in 12–24 months; registration\/reimbursement lags 18–36 months; prioritize high‑prevalence or high‑price niches.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTag\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003eKeytruda (2023)\u003c\/td\u003e\n\u003ctd\u003e$20.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina\u003c\/td\u003e\n\u003ctd\u003eBiologics (2024)\u003c\/td\u003e\n\u003ctd\u003e$70B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHome\u003c\/td\u003e\n\u003ctd\u003eHome infusion (2024)\u003c\/td\u003e\n\u003ctd\u003e$23.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare\u003c\/td\u003e\n\u003ctd\u003eUS orphan pop\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;200,000; price\u0026gt;$100k+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58097918312796,"sku":"halozyme-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/halozyme-bcg-matrix.png?v=1781796057","url":"https:\/\/pestel-analysis.com\/products\/halozyme-bcg-matrix","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}